Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents in Patients with Coronary Artery Disease: Primary Results from the BIONICS Trial.

Conclusions -In the present trial which allowed broad inclusion criteria, the novel RES met the prespecified criteria for noninferiority compared with ZES for the primary endpoint of target lesion failure at 12 months, and had similar measures of late lumen loss. These findings support the safety and efficacy of RES in patients representative of clinical practice. Clinical Trial Registration -URL: www.ClinicalTrials.gov Unique Identifier: NCT01995487. PMID: 28794001 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28794001?dopt=Abstract

Source: Circulation - August 9, 2017 Category: Cardiology Authors: Kandzari DE, Smits PC, Love MP, Ben-Yehuda O, Banai S, Robinson SD, Jonas M, Kornowski R, Bagur R, Iniguez A, Danenberg HD, Feldman RL, Jauhar R, Chandna H, Parikh MA, Perlman GY, Balcells M, Markham PM, Ozan MO, Genereux P, Edelman E, Leon MB, Stone GW Tags: Circulation Source Type: research